Anti-Human CD40 (Clone HB-14) - Dylight® 650
| Code | Size | Price |
|---|
| LEI-C1038-25ug | 25 ug | £159.00 |
Quantity:
| LEI-C1038-100ug | 100 ug | £271.00 |
Quantity:
| LEI-C1038-500ug | 500 ug | £673.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: Mouse IgG1 κ
Antibody Clonality: Monoclonal
Antibody Clone: HB-14
Regulatory Status: RUO
Target Species: Human
Application: Functional Study
Shipping:
2 - 8°C Wet Ice
Storage:
This DyLight® 650 conjugate is stable when stored at 2-8°C. Do not freeze.
Further Information
Antigen Distribution:
CD40 is widely expressed on antigen-presenting cells such as dendritic cells, B cells, macrophages, and monocytes, in addition to non-immune endothelial cells, basal epithelial cells, and a variety of tumors.
Concentration:
0.2 mg/ml
Conjugate/Tag/Label:
DyLight® 650
Format:
This DyLight® 650 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This DyLight® 650 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Immunogen:
Recombinant protein of CD40 protein
Long Description:
CD40 is a 48 kD type I transmembrane glycoprotein that is a member of the TNFR superfamily. CD40, in association with its ligand CD154 (CD40L) - a 39 kD protein, acts as a costimulatory molecule for the activation of B cells, dendritic cells, monocytes, and other antigen-presenting cells. CD40 is involved in Ig isotype switching and dendritic cell maturation, as well as the activation, differentiation, and proliferation of B cells. CD40 interacts with TNFR2 and is involved in the regulation of signal transduction. CD40 is a potential target for cancer immunotherapy; blocking the interaction of CD40 with its ligand (CD154) is the sought-after therapeutic objective for preventing and/or improving both autoimmune diseases and transplant rejection. Studies have shown that monoclonal antibodies that block CD154 in human clinical trials resulted in unanticipated vascular complications. Hence, an interest in the therapeutic potential for antagonist mAbs specific to human CD40 is emerging. Antibodies of particular therapeutic interest are those that do not inhibit CD40 signaling via physical competition with CD154. Additionally, the interaction of CD40 and its ligand (CD154) is found to be essential for amyloid-beta-induced microglial activation, thus playing a significant part in Alzheimer's disease pathogenesis. The anti-CD40 HB-14 clone was generated as part of a panel submitted to the Fifth International Leukocyte Differentiation Antigen Workshop1.
NCBI Gene:
958
Target:
CD40
References
1. Katira A, Holder MJ, Pound JD, and Gordon J. 1995. CD40 Workshop Panel Report. In Schlossman SF, Boumsell L, Gilks W, Harlan JM, Kishimoto T, Morimoto C, Ritz J, Shaw S, Silverstein R, Springer T, Tedder TF, and Todd RF, eds, Leukocyte Typing V, p. 547. Oxford University Press, Oxford. 2. Herbert J. Thesis: The regulation of specific antibody secretion by human B cells through contact and non-contact dependent mechanisms. 1996. https://discovery.ucl.ac.uk/id/eprint/10100666/1/out.pdf 3. Zhou LJ, Tedder TF. Proc Natl Acad Sci U S A. 93(6):2588-2592. 1996. 4. Tan PH, Beutelspacher SC, Xue SA, et al. Blood. 105(10):3824-3832. 2005. 5. Iwata Y, Matsushita T, Horikawa M, et al. Blood. 117(2):530-541. 2011. 6. Bacher P, Schink C, Teutschbein J, et al. J Immunol. 190(8):3967-3976. 2013. 7. Bacher P, Heinrich F, Stervbo U, et al. Cell. 167(4):1067-1078.e16. 2016. 8. Mura M, Chaudhury S, Farooq F, et al. MethodsX. 22;7:101005. 2020. 9. Pound JD, Challa A, Holder MJ, et al. Int Immunol. 11(1):11-20. 1999.